
    
      Secondary objective:

      To determine and compare the efficacy, safety, tolerability and immunogenicity of PEG-Intron
      1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W + Ribavirin
      800-1400 mg PO daily
    
  